OBJECTIVES: To evaluate the long-term health outcomes associated with Liraglutide 1.2 and 1.8 mg versus Glimepiride 4mg all combined with Metformin in Asian patients with type 2 diabetes (T2D).  METHODS: A published and validated computer simulation model of diabetes (CORE Diabetes Model) was used to make the projection of long-term health outcomes (30 years). Simulated cohorts and treatment effects were derived from 928 T2D patients in the NCT00614120 trial held in China, South Korea and India. HbA1C was significantly reduced in Liraglutide 1.2mg, Liraglutide 1.8mg, and Glimepiride groups (-1.3%, -1.4%, and -1.3% respectively). Liraglutide treatments led to greater reduction in Body Mass Index and systolic blood pressure versus Glimepride. No major hypoglycemia was reported in Liraglutide groups, while the rate of major hypoglycemia for Glimepride was 0.029 per patient-year. The rate of minor hypoglycemia was lower in Liraglutide groups than Glimepiride. An annual discounting rate of 3% was used for health and cost outcomes. One-way sensitivity analysis was performed. RESULTS: The treatments of Liraglutide compared with Glimepiride were projected to reduce the cumulative incidences of diabetes complications and improve long term health outcomes for patients with T2D. For Liraglutide 1.2mg, the cumulative incidences of background retinopathy, end stage renal disease, ulcer, and congestive heart failure event were reduced 0.20%, 0.086%, 0.020% and 0.53% respectively, discounted life expectancy was increased 0.058 year and quality adjusted life years (QALY) was increased 0.11 QALY. For Liraglutide 1.8mg, the incidences reduction were 0.61%, 0.12%, 0.34% and 0.63% respectively, discounted life expectancy was improved 0.051 year, and 0.107 QALY.  CONCLUSIONS: Liraglutide 1.2mg and 1.8mg therapy could delay the onset of diabetes complications and reduced related cumulative incidences over patient lifetimes compared with Glimepiride. It improved the life expectancy and quality adjusted life expectancy in Asian patients with T2D.